Last updated on July 2019

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Brief description of study

This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.

Detailed Study Description

The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.

Clinical Study Identifier: NCT03815383

Find a site near you

Start Over